Skip to main content

Table 1 Pts receiving locoregional Tx at first progression.

From: Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Locoregional Tx

# pts

# pts achieving ≥1yr

disease control

CNS, surgery and/or RT

9/80 (11%)

5/9 (56%)

Non-CNS, surgery

11/80 (14%)

8/11 (73%)

Non-CNS, RT

6/80 (8%)

3/6 (50%)

Ablation

2/80 (3%)

1/2 (50%)